Key Findings
uniQure has released updated four-year data from its Phase 1/2 study of ifezuntirgene inilparvovec (AMT-130), a gene therapy for Huntington’s disease, demonstrating a ‘meaningful slowing of disease progression’ in 12 patients. The therapy achieved a 44% reduction in progression rate on the cUHDRS (composite Unified Huntington’s Disease Rating Scale) and a 61% reduction on the TFC (Total Functional Capacity) scale, compared to historical controls. Despite these positive outcomes, concerns regarding potential waning efficacy led to a drop in the company’s stock value.
Technical & Clinical Details
AMT-130 is an AAV (adeno-associated virus)-based gene therapy designed to suppress the expression of the mutant huntingtin gene, the underlying cause of Huntington’s disease. The therapy is delivered directly into the brain via a single surgical procedure, aiming to reduce the production of the toxic mutant huntingtin protein. The long-term data showed a favorable safety profile, with no drug-related serious adverse events reported over the four-year follow-up period. The 12 patients in the study were in the early-to-mid stages of the disease, and the sustained clinical benefit highlights the potential of this targeted genetic intervention. Efficacy was primarily measured by neurological and functional assessments, demonstrating statistically significant improvements in key disease progression metrics.
Background & Context
Huntington’s disease is a devastating, inherited neurodegenerative disorder for which there is currently no cure or disease-modifying treatment. Existing therapies primarily manage symptoms, offering no impact on the relentless progression of the disease. Gene therapies like AMT-130 represent a paradigm shift by addressing the root genetic cause, holding the promise of altering the disease trajectory and significantly improving patients’ quality of life. The development of AAV-mediated gene therapies for neurological disorders is a highly active and promising field, with a focus on achieving durable expression and a safe delivery profile within the central nervous system.
Strategic Significance & Outlook
AMT-130 is currently under regulatory review by both the U.S. Food and Drug Administration (FDA) and the UK regulatory bodies. A potential approval would mark a historic milestone as the first disease-modifying treatment for Huntington’s disease, fundamentally changing the therapeutic landscape. While concerns about long-term durability and the potential need for redosing may linger, the substantial slowing of disease progression observed remains a critical achievement. uniQure is expected to continue optimizing its clinical strategy, potentially exploring dose adjustments or retreatment options to enhance sustained efficacy and address remaining uncertainties for this severe, unmet medical need.
Source: https://pharmaphorum.com/news/uniqure-falls-long-term-huntingtons-gene-therapy-data
Get our weekly technology intelligence — free
Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.
Subscribe Free — Weekly Tech Intelligence
By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.
- Your email and selected fields are used only to deliver the newsletter.
- We never share your information with third parties.
- You can unsubscribe anytime via the link in each email.
See our Privacy Policy for details.
Takes about a minute · Unsubscribe anytime
